A systematic genome-wide mapping of oncogenic mutation selection during CRISPR-Cas9 genome editing

Sanju Sinha, Karina Barbosa, Kuoyuan Cheng, Mark D. M. Leiserson, Prashant Jain, Anagha Deshpande, David M. Wilson, Bríd M. Ryan, Ji Luo, Ze’ev A. Ronai, Joo Sang Lee, Aniruddha J. Deshpande () and Eytan Ruppin ()
Additional contact information
Sanju Sinha: National Institutes of Health
Karina Barbosa: Sanford Burnham Prebys Medical Discovery Institute
Kuoyuan Cheng: National Institutes of Health
Mark D. M. Leiserson: University of Maryland
Prashant Jain: Sanford Burnham Prebys Medical Discovery Institute
Anagha Deshpande: Sanford Burnham Prebys Medical Discovery Institute
David M. Wilson: National Institutes of Health
Bríd M. Ryan: National Institutes of Health
Ji Luo: National Institute of Health
Ze’ev A. Ronai: Sanford Burnham Prebys Medical Discovery Institute
Joo Sang Lee: Sungkyunkwan University School of Medicine
Aniruddha J. Deshpande: Sanford Burnham Prebys Medical Discovery Institute
Eytan Ruppin: National Institutes of Health

Nature Communications, 2021, vol. 12, issue 1, 1-13

Abstract: Abstract Recent studies have reported that genome editing by CRISPR–Cas9 induces a DNA damage response mediated by p53 in primary cells hampering their growth. This could lead to a selection of cells with pre-existing p53 mutations. In this study, employing an integrated computational and experimental framework, we systematically investigated the possibility of selection of additional cancer driver mutations during CRISPR-Cas9 gene editing. We first confirm the previous findings of the selection for pre-existing p53 mutations by CRISPR-Cas9. We next demonstrate that similar to p53, wildtype KRAS may also hamper the growth of Cas9-edited cells, potentially conferring a selective advantage to pre-existing KRAS-mutant cells. These selective effects are widespread, extending across cell-types and methods of CRISPR-Cas9 delivery and the strength of selection depends on the sgRNA sequence and the gene being edited. The selection for pre-existing p53 or KRAS mutations may confound CRISPR-Cas9 screens in cancer cells and more importantly, calls for monitoring patients undergoing CRISPR-Cas9-based editing for clinical therapeutics for pre-existing p53 and KRAS mutations.

Date: 2021
References: View references in EconPapers View complete reference list from CitEc
Citations: View citations in EconPapers (1)

Downloads: (external link)
https://www.nature.com/articles/s41467-021-26788-6 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:12:y:2021:i:1:d:10.1038_s41467-021-26788-6

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-021-26788-6

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().